$ENTA News
Last published 2w ago
- 2w agoENTAEnanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)Business WireGlobal Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 Enanta Pharmaceuticals, Inc.
- 4w agoENTAEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
- 1mo agoENTABAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - ENANTA PHARMACEUTICALS INCEarnings Call TranscriptsWelcome back. Good afternoon, everyone. I'm Brian Scorni. I am one of Baird's Senior Biotech Analysts. With me for the next Q&A is Antifarmaceuticals. This is a company I've covered a very long time, Rich. We've known ea
- 1mo agoENTABAIRD 2026 GLOBAL HEALTHCARE CONFERENCE - ENANTA PHARMACEUTICALS INCEarnings Call TranscriptsWelcome back. Good afternoon, everyone. I'm Brian Scorni. I am one of Baird's Senior Biotech Analysts. With me for the next Q&A is Antifarmaceuticals. This is a company I've covered a very long time, Rich. We've known ea
- 2mo agoENTAEnanta Pharmaceuticals to Participate in September Investor ConferencesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management
- 3mo agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026Business WireDosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline
- 4mo agoENTAEnanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C VirusBusiness WireMAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV Patients Immediately at
- 4mo agoENTAEnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)Business WireRegistrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in
- 5mo agoENTAEnanta Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference in New York - ENANTA PHARMACEUTICALS INCEarnings Call TranscriptsGood at what still still not still morning but good morning really appreciate everyone's attendance and it's been really enjoyable seeing everyone in New York enjoying this conference my name is Akash Tiwari I head our p
- 5mo agoENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D.,
- 6mo agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026Business WireDosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for
- 6mo agoENTAEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an
- 7mo agoENTAEnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaBusiness WirePhase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a
- 7mo agoENTAEnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an
- 7mo agoENTAEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from
- 8mo agoENTAEnanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that members of management
- 9mo agoENTAEnanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual MeetingBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data for
- 9mo agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025Business WireConducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus
- 10mo agoENTAEnanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today
- 11mo agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025Business WireAnnounces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic
- 1y agoENTAEnanta Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of
- 1y agoENTAEnanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025Business WireZelicapavir Results in Shortened Symptom Duration in Pediatric Patients EDP-323 is Highly Effective in a Post-Exposure Prophylaxis Setting Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage
- 1y agoENTAEnanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
- 1y agoENTAEnanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that it has closed its
- 1y agoENTAEnanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized
- 1y agoENTAEnanta Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten
- 1y agoENTAEnanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk AdultsBusiness Wire6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75
- 1y agoENTAEnanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk AdultsBusiness WireConference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m.
- 1y agoENTAEnanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. "The entire Enanta team mourns the loss of
- 1y agoENTAEnanta Pharmaceuticals to Participate in September Investor ConferencesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management
- 1y agoENTAEnanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European UnionBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed
- 1y agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025Business WireOn Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H
- 1y agoENTARNTXWVEXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationPR NewswireXtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery,...
- 1y agoENTAEnanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" SeriesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management
- 1y agoENTAEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery SeriesBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management
- 1y agoENTAEnanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C VirusBusiness WireMAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now
- 1y agoENTAEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D.,
- 1y agoENTAEnanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID MeetingBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's
- 1y agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025Business WireMet Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 STAT6 Program Progressing with
- 1y agoENTAEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025Business WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from the Company's Phase
- 1y agoENTAEnanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will
- 1y agoENTAEnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV SymposiumBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three
- 1y agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024Business WireOn Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling
- 1y agoENTAEnanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President
- 1y agoENTAEnanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement LawsuitBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District
- 1y agoENTAEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)Business WireObserved an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of
- 1y agoENTAEnanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)Business WireConference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for
- 1y agoENTAEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024Business WireOn Track to Report Topline Results for RSVPEDs, a Phase 2 Study of Zelicapavir in Infants and Children Infected with Respiratory Syncytial Virus (RSV), in December Announced Positive Topline Results for EDP-323 in
- 2y agoENTAEnanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)Business WireTreatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and
- 2y agoENTAEnanta Pharmaceuticals to Participate in Investor Conferences in SeptemberBusiness WireEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will